Biomarkers for Prostate Cancer Diagnosis from Genetic Perspectives

Document Type : Review

Authors

1 Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran

2 Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Department of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

10.22034/tru.2020.258970.1053

Abstract

Prostate cancers (PC) are mainly diagnosed by screening prostate-specific antigen (PSA) quantity in the blood or a digital rectal exam (DRE). PC typically does not have symptoms contrary to advanced cancers that are diagnosed due to significant symptoms. Diagnosis of PC is established with the transrectal ultrasound (TRUS) guided biopsy. Estimation of the free PSA to total PSA (fPSA/tPSA) ratio and Multiparametric-magnetic resonance imaging (mp-MRI) can expand the diagnosis accuracy. Several molecular biomarkers have improved PC diagnosis like Confirm MDx, Prostate Core Mitomic Test (PCMT), TMPRSS2-ERG, The PTEN gene, ProMark, 4K score including, and Circulating Tumor Cells (CTCs). These molecular biomarkers are considered both genetic and epigenetic (DNA methylation) hallmarks of PC. We aim to present an overview of all molecular biomarkers of PC and their implication in improving the management of PC patients.

Highlights

  • Estimation of the fPSA/tPSA ratio and Multiparametric-magnetic resonance imaging (mp-MRI) can expand the prostate cancer diagnosis accuracy.
  • Several biomarkers are considered in testing panels like ConfirmMDx, Prostate Core Mitomic Test (PCMT), TMPRSS2-ERG, The PTEN gene, ProMark, 4K score.
  • Liquid biopsy components like can CTCs help the clinician to decide in the re-biopsy step.

Keywords

Main Subjects


1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians. 2019;69(1):7-34.
2. Ruijter E, van de Kaa C, Miller G, Ruiter D, Debruyne F, Schalken J. Molecular genetics and epidemiology of prostate carcinoma. Endocrine reviews. 1999;20(1):22-45.
3. Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera J-M, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215-28.
4. Negoita S, Feuer EJ, Mariotto A, Cronin KA, Petkov VI, Hussey SK, et al. Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics. Cancer. 2018;124(13):2801-14.
5. Drazer MW, Huo D, Eggener SE. National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen–based screening. Journal of Clinical Oncology. 2015;33(22):2416-23.
6. Salinas CA, Tsodikov A, Ishak-Howard M, Cooney KA. Prostate cancer in young men: an important clinical entity. Nature Reviews Urology. 2014;11(6):317.
7. Bunker CH, Patrick AL, Konety BR, Dhir R, Brufsky AM, Vivas CA, et al. High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey. Cancer Epidemiology and Prevention Biomarkers. 2002;11(8):726-9.
8. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. The prostate. 1990;17(4):337-47.
9. Kiciński M, Vangronsveld J, Nawrot TS. An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis. PloS one. 2011;6(10):e27130.
10. Albright F, Stephenson RA, Agarwal N, Teerlink CC, Lowrance WT, Farnham JM, et al. Prostate cancer risk prediction based on complete prostate cancer family history. The Prostate. 2015;75(4):390-8.
11. Kvåle R, Møller B, Wahlqvist R, Fosså SD, Berner A, Busch C, et al. Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population‐based study. BJU international. 2009;103(12):1647-54.
12. Scattoni V, Maccagnano C, Capitanio U, Gallina A, Briganti A, Montorsi F. Random biopsy: when, how many and where to take the cores? World journal of urology. 2014;32(4):859-69.
13. Örtegren J, Holmberg JT, Lekås E, Mana S, Mårtensson S, Richthoff J, et al. A randomised trial comparing two protocols for transrectal prostate repeat biopsy: six lateral posterior plus six anterior cores versus a standard posterior 12-core biopsy. Scandinavian journal of urology. 2019:1-5.
14. Oesterling JE, Rice DC, Glenski WJ, Bergstralh EJ. Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate-specific antigen concentration. Urology. 1993;42(3):276-82.
15. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute. 2006;98(8):529-34.
16. Ankerst DP, Hoefler J, Bock S, Goodman PJ, Vickers A, Hernandez J, et al. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low-vs high-grade prostate cancer. Urology. 2014;83(6):1362-8.
17. Oesterling JE, Jacobsen SJ, Cooner WH. The Use of Age-Specific Reference Ranges for Serum Prostate Specific Anitgen in Men 60 years Old or Older. The Journal of urology. 1995;153(4):1160-3.
18. Lee R, Localio AR, Armstrong K, Malkowicz SB, Schwartz JS, Group FPS. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology. 2006;67(4):762-8.
19. Tang P, Du W, Xie K, Deng X, Fu J, Chen H, et al., editors. Transition zone PSA density improves the prostate cancer detection rate both in PSA 4.0–10.0 and 10.1–20.0 ng/ml in Chinese men. Urologic Oncology: Seminars and Original Investigations; 2013: Elsevier.
20. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, et al. A multicenter study of [-2] pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. The Journal of urology. 2011;185(5):1650-5.
21. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. Jama. 1997;277(18):1445-51.
22. Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. European urology. 2016;69(3):428-35.
23. Ghai S, Haider MA. Multiparametric-MRI in diagnosis of prostate cancer. Indian journal of urology: IJU: journal of the Urological Society of India. 2015;31(3):194.
24. Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, et al. Screening for prostate cancer: a review of the evidence for the US Preventive Services Task Force. Annals of internal medicine. 2011;155(11):762-71.
25. Schimmöller L, Quentin M, Arsov C, Hiester A, Buchbender C, Rabenalt R, et al. MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy. European radiology. 2014;24(10):2582-9.
26. Panebianco V, Barchetti F, Sciarra A, Ciardi A, Indino EL, Papalia R, et al., editors. Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. Urologic Oncology: Seminars and Original Investigations; 2015: Elsevier.
27. Lawrence EM, Gallagher FA, Barrett T, Warren AY, Priest AN, Goldman DA, et al. Preoperative 3-T diffusion-weighted MRI for the qualitative and quantitative assessment of extracapsular extension in patients with intermediate-or high-risk prostate cancer. American Journal of Roentgenology. 2014;203(3):W280-W6.
28. Jie C, Rongbo L, Ping T. The value of diffusion-weighted imaging in the detection of prostate cancer: a meta-analysis. European radiology. 2014;24(8):1929-41.
29. Clarke RA, Zhao Z, Guo A-Y, Roper K, Teng L, Fang Z-M, et al. New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression. PloS one. 2009;4(3):e4995.
30. Crawford ED, Rove KO, Trabulsi EJ, Qian J, Drewnowska KP, Kaminetsky JC, et al. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. The Journal of urology. 2012;188(5):1726-31.
31. Cui Y, Cao W, Li Q, Shen H, Liu C, Deng J, et al. Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis. Scientific reports. 2016;6:25776.
32. Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, et al. Analytical validation of the Onco type DX prostate cancer assay–a clinical RT-PCR assay optimized for prostate needle biopsies. BMC genomics. 2013;14(1):690.
33. Cooperberg M, Simko J, Falzarano S, Maddala T, Chan J, Cowan J, et al. 2131 Development and validation of the biopsy-based genomic prostate score (GPS) as a predictor of high grade or extracapsular prostate cancer to improve patient selection for active surveillance. The Journal of Urology. 2013.
34. Chang EM, Punglia RS, Steinberg ML, Raldow AC. Cost Effectiveness of the Oncotype DX Genomic Prostate Score for Guiding Treatment Decisions in Patients With Early Stage Prostate Cancer. Urology. 2019;126:89-95.
35. Klein EA, Maddala T, Millward C, Cherbavaz DB, Falzarano SM, Knezevic D, et al. Development of a needle biopsy-based genomic test to improve discrimination of clinically aggressive from indolent prostate cancer. American Society of Clinical Oncology; 2012.
36. Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PloS one. 2013;8(6):e66855.
37. Loeb S, Ross AE. Genomic testing for localized prostate cancer: where do we go from here? Curr Opin Urol. 2017;27(5):495-9.
38. Marrone M, Potosky AL, Penson D, Freedman AN. A 22 gene-expression assay, Decipher®(GenomeDx Biosciences) to predict five-year risk of metastatic prostate cancer in men treated with radical prostatectomy. PLoS currents. 2015;7.
39. Waterhouse Jr RL, Van Neste L, Moses KA, Barnswell C, Silberstein JL, Jalkut M, et al. Evaluation of an Epigenetic Assay for predicting repeat prostate biopsy outcome in African American men. Urology. 2019;128:62-5.
40. Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ, et al. NCCN guidelines insights: prostate cancer early detection, version 2.2016. Journal of the National Comprehensive Cancer Network. 2016;14(5):509-19.
41. Partin AW, Van Neste L, Klein EA, Marks LS, Gee JR, Troyer DA, et al. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. The Journal of urology. 2014;192(4):1081-7.
42. Legisi L, DeSa E, Qureshi MN. Use of the prostate core mitomic test in repeated biopsy decision-making: real-world assessment of clinical utility in a multicenter patient population. American health & drug benefits. 2016;9(9):497.
43. Blute Jr ML, Abel EJ, Downs TM, Kelcz F, Jarrard DF. Addressing the need for repeat prostate biopsy: new technology and approaches. Nature Reviews Urology. 2015;12(8):435.
44. Wang Z, Wang Y, Zhang J, Hu Q, Zhi F, Zhang S, et al. Significance of the TMPRSS2:ERG gene fusion in prostate cancer. Mol Med Rep. 2017;16(4):5450-8.
45. Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, et al., editors. Combining urinary detection of TMPRSS2: ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urologic Oncology: Seminars and Original Investigations; 2013: Elsevier.
46. Geybels MS, Fang M, Wright JL, Qu X, Bibikova M, Klotzle B, et al. PTEN loss is associated with prostate cancer recurrence and alterations in tumor DNA methylation profiles. Oncotarget. 2017;8(48):84338-48.
47. Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA, et al. Clinical implications of PTEN loss in prostate cancer. Nature Reviews Urology. 2018;15:222.
48. Falzarano S, Ferro M, Bollito E, Klein E, Carrieri G, Magi-Galluzzi C. Novel biomarkers and genomic tests in prostate cancer: a critical analysis. Minerva urologica e nefrologica= The Italian journal of urology and nephrology. 2015;67(3):211-31.
49. Carroll PH, Mohler JL. NCCN guidelines updates: prostate cancer and prostate cancer early detection. Journal of the National Comprehensive Cancer Network. 2018;16(5S):620-3.
50. Zappala SM, Dong Y, Linder V, Reeve M, Sjoberg DD, Mathur V, et al. The 4Kscore blood test accurately identifies men with aggressive prostate cancer prior to prostate biopsy with or without DRE information. International journal of clinical practice. 2017;71(6):e12943.
51. Pantel K, Alix-Panabieres C. Liquid biopsy in 2016: Circulating tumour cells and cell-free DNA in gastrointestinal cancer. Nature Reviews Gastroenterology & Hepatology. 2017;14(2):73.
52. Xu L, Mao X, Grey A, Scandura G, Guo T, Burke E, et al. Non-invasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells. The Journal of urology. 2019:10.1097/JU. 0000000000000475.
53. Bailey PC, Martin SS. Insights on CTC Biology and Clinical Impact Emerging from Advances in Capture Technology. Cells. 2019;8(6):553.